BEIJING (Reuters): A Covid-19 vaccine developed by a Beijing firm linked to Sinopharm has a protection rate of 79.34% against the disease, the firm said in a statement on Wednesday (Dec 30).
Beijing Biological Products Institute Co Ltd said it had applied to the National Medical Products Administration for conditional approval of the vaccine.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
